Amgen parathyroid drug succeeds in late-stage trial
(Reuters) - (This story corrects headline and first paragraph in Aug. 18 story to replace "thyroid" with "parathyroid"))
Drugmaker Amgen Inc said its experimental drug to reduce parathyroid levels in patients with chronic kidney disease met the main goal in a late-stage trial.
The drug, AMG 416, treats hyperparathyroidism, or excessive secretion of parathyroid hormone, in kidney disease patients.
The results follow the recent announcement of positive data from a placebo-controlled late-stage study of AMG 416, which was similar in design and size.
(Reporting By Amrutha Penumudi in Bangalore)
- Total CEO de Margerie killed in Moscow as jet hits snow plow |
- Sweden gets two new sightings, as hunt for undersea intruder goes on
- Pistorius starts five-year term for killing Reeva Steenkamp
- U.S. to funnel travelers from Ebola-hit region through five airports
- Ebola crisis turns a corner as U.S. issues new treatment protocols